Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VCYT Stock Forecast 2026-2027
$42.45
Current Price
$3.36B
Market Cap
Buy 9
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to VCYT Price Targets
+20.1%
To High Target of $51.00
+13.1%
To Median Target of $48.00
+1.3%
To Low Target of $43.00
VCYT Price Momentum
-2.5%
1 Week Change
-2.5%
1 Month Change
+1.7%
1 Year Change
+0.8%
Year-to-Date Change
-16.3%
From 52W High of $50.71
+87.7%
From 52W Low of $22.61
📊 TOP ANALYST CALLS
Did VCYT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Veracyte is one of their latest high-conviction picks.
Latest VCYT Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, VCYT has a bullish consensus with a median price target of $48.00 (ranging from $43.00 to $51.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $42.45, the median forecast implies a 13.1% upside. This outlook is supported by 9 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Mike Matson at Needham, projecting a 20.1% upside. Conversely, the most conservative target is provided by Kyle Mikson at Canaccord Genuity, suggesting a 1.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VCYT Analyst Ratings
9
Buy
2
Hold
1
Sell
VCYT Price Target Range
Low
$43.00
Average
$48.00
High
$51.00
Current: $42.45
Latest VCYT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VCYT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 5, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $50.00 |
| Dec 2, 2025 | Morgan Stanley | Tejas Savant | Underweight | Maintains | $48.00 |
| Nov 11, 2025 | Morgan Stanley | Tejas Savant | Underweight | Maintains | $40.00 |
| Nov 5, 2025 | Needham | Mike Matson | Buy | Maintains | $44.00 |
| Nov 5, 2025 | Guggenheim | Subbu Nambi | Buy | Maintains | $45.00 |
| Nov 5, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $43.00 |
| Nov 5, 2025 | UBS | Lu Li | Buy | Maintains | $48.00 |
| Oct 20, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Initiates | $40.00 |
| Oct 17, 2025 | Freedom Capital Markets | Keith Hinton | Buy | Initiates | $45.00 |
| May 8, 2025 | UBS | Lu Li | Buy | Maintains | $42.00 |
| May 8, 2025 | Needham | Mike Matson | Buy | Maintains | $41.00 |
| Apr 9, 2025 | Guggenheim | Subbu Nambi | Buy | Maintains | $37.00 |
| Mar 26, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $45.00 |
| Mar 20, 2025 | Craig-Hallum | John Wilkin | Buy | Initiates | $45.00 |
| Feb 25, 2025 | Needham | Mike Matson | Buy | Reiterates | $51.00 |
| Feb 25, 2025 | UBS | Lu Li | Buy | Maintains | $49.00 |
| Feb 25, 2025 | Guggenheim | Subbu Nambi | Buy | Reiterates | $45.00 |
| Jan 29, 2025 | Needham | Mike Matson | Buy | Maintains | $51.00 |
| Dec 5, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Downgrade | $37.00 |
| Nov 18, 2024 | Morgan Stanley | Tejas Savant | Underweight | Maintains | $28.00 |
Veracyte Inc. (VCYT) Competitors
The following stocks are similar to Veracyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VCYT
Veracyte
mkt cap
3.32B
Veracyte Inc. (VCYT) Financial Data
Veracyte Inc. has a market capitalization of $3.36B with a P/E ratio of 114.6x. The company generates $495.14M in trailing twelve-month revenue with a 6.1% profit margin.
Revenue growth is +13.8% quarter-over-quarter, while maintaining an operating margin of +17.5% and return on equity of +2.5%.
Valuation Metrics
Market Cap
$3.36B
Enterprise Value
$3.11B
P/E Ratio
114.6x
PEG Ratio
4.4x
Price/Sales
7.0x
Growth & Margins
Revenue Growth (YoY)
+13.8%
Gross Margin
+69.2%
Operating Margin
+17.5%
Net Margin
+6.1%
EPS Growth
+26.3%
Financial Health
Cash/Price Ratio
+10.9%
Current Ratio
6.2x
Debt/Equity
3.2x
ROE
+2.5%
ROA
+2.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Veracyte Inc. (VCYT) Business Model
About Veracyte Inc.
What They Do
Provides genomic diagnostics for improved patient outcomes.
Business Model
Veracyte generates revenue by offering advanced molecular diagnostic tests that enable precise and less invasive diagnoses. Their tests help reduce unnecessary surgeries and procedures, thereby saving costs for healthcare systems while improving treatment decisions in critical areas such as oncology and pulmonology.
Additional Information
The company leverages proprietary genomic platforms and algorithms to enhance diagnostic accuracy, positioning itself within the rapidly growing field of precision medicine. This aligns with broader trends towards value-based care and highlights the increasing demand for personalized medical solutions.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
824
CEO
Mr. Marc A. Stapley
Country
United States
IPO Year
2013
Website
www.veracyte.comVeracyte Inc. (VCYT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
Natera teams up with NVIDIA to train multimodal AI models, aiming to improve precision care through faster, scalable analysis of complex medical data.
Jan 13, 2026
By Zacks Equity Research
Analyst Blog
BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers
Butterfly Network targets a 2026 Beam Steering API, opening core imaging to developers and enabling AI tools in Butterfly Garden.
Jan 07, 2026
By Zacks Equity Research
Analyst Blog
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.
Jan 05, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Veracyte, Inc. (Nasdaq: VCYT) anticipates Q4 2025 revenue between $138M and $140M, reflecting a 16%-18% increase from Q4 2024.
Why It Matters
Veracyte's projected revenue growth signals strong demand for its cancer diagnostics, potentially enhancing investor confidence and driving stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Veracyte, Inc. (Nasdaq: VCYT) will present at the J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. PT. Live audio and a replay will be available on their website.
Why It Matters
Veracyte's participation in a major healthcare conference highlights its visibility and potential growth in the cancer diagnostics market, signaling potential investment opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
VCYT, IDXX, and ISRG are experiencing growth driven by AI advancements in medical instruments, despite facing weak industry returns and cost pressures.
Why It Matters
GenAI advancements in VCYT, IDXX, and ISRG may enhance their market positions, potentially driving future profitability despite current industry challenges.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
VCYT's Afirma and Decipher tests drive significant volume growth; however, increasing macro costs and expenses may impact future outlook. The company maintains a debt-free balance sheet.
Why It Matters
VCYT's strong test volume growth signals potential revenue increases, but rising costs may impact profitability, affecting future stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Zacks Premium offers Style Scores to assist all types of investors—value, growth, or momentum—in identifying strong stocks more easily.
Why It Matters
Zacks Style Scores can enhance stock selection for various investment strategies, potentially leading to better portfolio performance and informed decision-making.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Veracyte's stock rose 27.5% following Q3 earnings and revenues that surpassed estimates, fueled by robust growth in Decipher and Afirma tests.
Why It Matters
Veracyte's 27.5% surge indicates strong market confidence following better-than-expected Q3 earnings, reflecting growth potential in key products, which may attract more investment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About VCYT Stock
What is Veracyte Inc.'s (VCYT) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Veracyte Inc. (VCYT) has a median price target of $48.00. The highest price target is $51.00 and the lowest is $43.00.
Is VCYT stock a good investment in 2026?
According to current analyst ratings, VCYT has 9 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $42.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VCYT stock?
Wall Street analysts predict VCYT stock could reach $48.00 in the next 12 months. This represents a 13.1% increase from the current price of $42.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Veracyte Inc.'s business model?
Veracyte generates revenue by offering advanced molecular diagnostic tests that enable precise and less invasive diagnoses. Their tests help reduce unnecessary surgeries and procedures, thereby saving costs for healthcare systems while improving treatment decisions in critical areas such as oncology and pulmonology.
What is the highest forecasted price for VCYT Veracyte Inc.?
The highest price target for VCYT is $51.00 from Mike Matson at Needham, which represents a 20.1% increase from the current price of $42.45.
What is the lowest forecasted price for VCYT Veracyte Inc.?
The lowest price target for VCYT is $43.00 from Kyle Mikson at Canaccord Genuity, which represents a 1.3% increase from the current price of $42.45.
What is the overall VCYT consensus from analysts for Veracyte Inc.?
The overall analyst consensus for VCYT is bullish. Out of 15 Wall Street analysts, 9 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $48.00.
How accurate are VCYT stock price projections?
Stock price projections, including those for Veracyte Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:45 AM UTC